Skip to main content

Seattle Genetics Value Stock - Dividend - Research Selection

Seattle Genetics

ISIN: US8125781026, WKN: 602322

Market price date: 11.01.2021
Market price: 179,04 USD




Seattle Genetics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 10-02-2020
Cash flow
Net operating cash flow -163.737.000
Capital Expenditures -70.753.000
Free cash flow -234.490.000
Balance sheet
Total Equity 1.876.290.000
Liabilities & Shareholders equity 2.205.870.000
Income statement
Net income -158.650.000
Eps (diluted) -0,960
Diluted shares outstanding 165.260.000
Net sales/revenue 916.713.000

Fundamental ratios calculated on: 11-01-2021

Ratios
Key figures 11-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI-7,19
ROE85,06
Income statement
P/E-186,50
Div. Yield0,00%
P/B0,00
P/S32,28


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSGEN
Market Capitalization29.360.091.136,00 USD
CountryUnited States
IndicesNASDAQ Comp.,NASDAQ 100
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.seattlegenetics.com


Description of the company

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company\'s earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.seattlegenetics.com